News Provided By – NUMINUS WELLNESS INC. (TSX-V:NUMI)
Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies
VANCOUVER, BC, Sept. 24, 2020 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.
Under its Health Canada licence for the production and extraction of psilocybin from mushrooms, Numinus intends to cultivate and harvest the mushrooms for a variety of purposes including:
- development of standardized extraction methods
- exploration of product formulations of naturally occurring psilocybin
- development and evaluation of qualitative and quantitative mycochemicals standardized test methodologies
- exploration of the ability to investigate naturally occurring psilocybin’s efficacy as an alternative supply to synthetic psilocybin currently used in research
- ultimately, the delivery of safe, evidence-based psilocybin-assisted psychotherapy at clinics including its own
“We are thrilled to start growing mushrooms at our laboratory under our Health Canada licence,” says Michael Tan, Chief Operating Officer. “We envision a day when the option of natural, plant-based psilocybin is available for use in therapies at Numinus Clinics and by others, and this is a tangible step towards that goal.”
Numinus’s vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated. From product development and supply, to analytics and testing, and including clinical protocol development and implementation science in partnership with leading research organizations, the ecosystem approach allows Numinus to ensure quality control and best-in-class delivery with steady revenue streams to support its developments.
Numinus continues to make progress in all units of its ecosystem. Other recent developments include:
Numinus Health — Upgrades have commenced on its existing wellness clinic for compliance to the Multidisciplinary Association of Psychedelics Studies (MAPS) specifications for psychedelic-assisted psychotherapies, to ready the clinic for delivery of therapies and to provide a blueprint for the expansion of Numinus clinics in a range of jurisdictions in the future. In addition, the Company is fast-tracking plans for virtual delivery of transformative health solutions to counter COVID-related risks.
Numinus R&D — Refinements are being implemented in the Company’s clinical protocols to support MDMA and psilocybin research, and partnership discussions with leading research organizations are progressing, with the goal of making these substances accessible in a research context before they are widely available on the market.
Numinus Bioscience — The laboratory is preparing to add additional revenue streams as a contract analytical and research lab for psychedelic substances including MDMA, psilocybin, psilocin, DMT, and mescaline under its Health Canada Controlled Drugs and Substances licence.
“Numinus is setting the stage – and establishing its leadership position – for a future state where psychedelic medicines are approved for clinical use outside of research,”– Payton Nyquvest, Founder, CEO, and Board Chair.
“We are progressing on our mission right now by creating the infrastructure and advancing evidence-based research to support routine clinical use in the health care system. We have the infrastructure, licenses, resources, and expertise to help hasten evidence-based accessibility to these treatments so we can, ultimately, help people heal and be well.”– Payton Nyquvest, Founder, CEO, and Board Chair.
READ OUR SPECIAL REPORT – TO DISCOVER HOW NUMINUS’ (TSX-V:NUMI) EXPERT TEAM IS AT THE FOREFRONT OF DEVELOPING HEALING TREATMENTS FOR THE MIND
Numinus is a Vancouver-based health care company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus’ ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten legal, for-profit psychedelic-assisted therapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available. Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly-owned subsidiary Salvation Botanicals) including a cannabis testing licence used for sustainable revenue to support the company’s psychedelic efforts. The company holds a dealers licence which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT and mescaline. Numinus is the only publicly listed company in Canada to be issued a Health Canada license to produce and extract psilocybin from mushrooms. These licences will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D leverages established relationships to position the Company for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Heath is dedicated to delivering therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — with psychedelic treatments at its core when approved for therapeutic and research use. For more information, visit www.numinus.ca.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.